BTK Degradation via Ubiquitin Proteasome Pathway, Nurix Therapeutics, Apr 15

The EPO Patent Bulletin published application EP3867242A1 on April 15, 2026, representing a new patent application by Nurix Therapeutics, Inc. for bifunctional compounds that degrade BTK through the ubiquitin proteasome pathway. The application covers heterocyclic compounds (C07D classifications) with therapeutic applications in oncology (A61P 35/00) and immunology (A61P 37/00). Designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

For pharmaceutical and biotechnology companies working in targeted protein degradation, this patent defines a structural approach to bifunctional degrader molecules directed at BTK. Parties seeking to develop BTK-targeted degraders in Europe should review this application's compound claims and scope to assess freedom-to-operate implications, and may wish to monitor the EPO prosecution record for any narrowing of claim scope during examination.